Danaher Corporation $DHR Stock Sold by OLD Second National Bank of Aurora

by · The Cerbat Gem

OLD Second National Bank of Aurora decreased its holdings in Danaher Corporation (NYSE:DHR – Free Report) by 81.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,184 shares of the conglomerate’s stock after selling 9,831 shares during the period. OLD Second National Bank of Aurora’s holdings in Danaher were worth $484,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Gunderson Capital Management LLC acquired a new position in Danaher during the third quarter worth $765,000. EP Wealth Advisors LLC acquired a new stake in shares of Danaher in the 2nd quarter worth $3,807,000. Frank Rimerman Advisors LLC increased its stake in shares of Danaher by 181.9% in the 3rd quarter. Frank Rimerman Advisors LLC now owns 40,855 shares of the conglomerate’s stock worth $9,051,000 after acquiring an additional 26,363 shares during the last quarter. Birch Hill Investment Advisors LLC increased its stake in shares of Danaher by 9.6% in the 3rd quarter. Birch Hill Investment Advisors LLC now owns 40,549 shares of the conglomerate’s stock worth $8,984,000 after acquiring an additional 3,553 shares during the last quarter. Finally, Forbes J M & Co. LLP raised its holdings in shares of Danaher by 141.6% during the 3rd quarter. Forbes J M & Co. LLP now owns 4,276 shares of the conglomerate’s stock worth $947,000 after acquiring an additional 2,506 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DHR has been the subject of a number of analyst reports. UBS Group reissued a “buy” rating and issued a $260.00 price objective on shares of Danaher in a report on Thursday. Guggenheim raised their price objective on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. TD Cowen lifted their target price on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday. Evercore reiterated an “outperform” rating and issued a $230.00 target price on shares of Danaher in a report on Monday, July 6th. Finally, Weiss Ratings upgraded shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $242.91.

View Our Latest Research Report on Danaher

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

  • Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, ahead of the $1.92 analyst consensus, while revenue increased 8.3% year over year to $6.55 billion. Biotechnology profitability and improving demand across several end markets supported the earnings beat. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
  • Positive Sentiment: Management raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, and biotechnology orders grew at a mid-teens rate. The company also highlighted margin expansion, improving customer demand, and artificial-intelligence capabilities that could support longer-term drug-discovery growth. Danaher: 3 Key Takeaways for Long-Term Investors
  • Positive Sentiment: Several analysts raised their price targets, including TD Cowen and JPMorgan to $270, Goldman Sachs to $275, and Stifel to $260. The upgrades reflect confidence in the earnings beat, improved execution, and the stronger profit outlook.
  • Neutral Sentiment: New CEO Julie Montgomery emphasized the need to improve execution and innovation. Investors are watching whether management can convert the company’s AI and biotechnology investments into sustained growth. Danaher Posts First Earnings Under New CEO
  • Negative Sentiment: Revenue was approximately in line with, or slightly below, estimates, while analysts cited tariff pressure and a cautious 2027 outlook. At roughly 41 times earnings, Danaher’s valuation leaves limited room for operational disappointment, contributing to the negative investor reaction despite the quarterly beat.

Danaher Price Performance

DHR stock opened at $229.86 on Friday. The business has a fifty day moving average of $215.76 and a two-hundred day moving average of $197.12. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The stock has a market cap of $161.59 billion, a price-to-earnings ratio of 40.83, a price-to-earnings-growth ratio of 2.95 and a beta of 0.76. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last posted its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.92 by $0.19. Danaher had a return on equity of 11.22% and a net margin of 16.91%. The company had revenue of $6.55 billion for the quarter, compared to the consensus estimate of $6.56 billion. During the same quarter in the previous year, the business earned $1.89 earnings per share. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, research analysts anticipate that Danaher Corporation will post 8.51 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio is presently 28.42%.

Danaher Company Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).